Targets › CLPP
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout May 2027.
Protease component of the ClpXP complex that cleaves peptides and various proteins in an ATP-dependent process. Has low peptidase activity in the absence of CLPX. The ClpXP complex can degrade CSN1S1, CSN2 and CSN3, as well as synthetic peptides (in vitro) and may be responsible for a fairly general and central housekeeping function rather than for the degradation of specific substrates. (UniProt, Q16740)
Open in Phaseline: the race on CLPP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sabine Mueller, MD, PhD | ONC206 DRD2 antagonist / ClpP agonist | DRD2, CLPP | Phase 1 | Diffuse Midline Glioma (DMG) | May 2027 |
Diffuse Midline Glioma (DMG) (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.